Dr Charlotte Waterworth

I wrote this article on behalf of the physician. The article is about his experience with
intrastromal corneal ring segments for the treatment of corneal ectatic disorders.

This was a magazine supplement containing a series of articles explaining how contact lenses can disrupt the balance of the ocular surface leading to dryness and discomfort, and how Bausch + Lomb designed a lens to address this problem.

I ghost-wrote this article on behalf of the clinicians and it was selected as the cover story. I have ghost-written over 30 articles for the trade press. This piece is just one example.

This article examined whether people really want choice in healthcare and the implications for patients and healthcare providers.

This interview piece appeared in a magazine for health members of Unite the Union, a UK-based trade union. I interviewed the leader of Unite (at that time) about a number of issues including the challenges faced by health workers.

I wrote this white paper for medeuronet (now known as Medivise Consulting). This in-depth piece explored whether EU public health systems should adopt the latest, and often expensive, medical technologies.

A short article about alternatives to Tamiflu (oseltamivir), an antiviral drug used for the treatment of influenza.

A short article on alternative treatments to the asthma treatment, Spiriva.

This was the second time I was invited to interview the UK Secretary of State for Health and Social Care - this time, Alan Johnson. Mr Johnson spoke with me about his plans for the National Health Service. The interview is on page 8 of the magazine, of which I was also the managing editor

I wrote this feature article on the importance of health education and the role of healthcare professionals in implementing preventative health measures.

When I was the managing editor of Unite Health, a magazine for NHS workers who were members of Unite the Union, I had the opportunity to interview Patricia Hewitt who was Secretary of State for Health and Social Care at that time. Getting an interview with such a high level member of the UK government isn't easy! However, Patricia invited me to Whitehall to discuss her vision for the health service

I researched and co-reported on a new diabetes treatment, Merck & Co. Inc.’s Januvia (sitagliptin), a first-in-class oral dipeptidyl peptidase-4 (DPP-IV) inhibitor. This piece of work involved leading a team of reporters, conducting interviews with endocrinologists, writing the final report and presenting the findings to the client.